What is Melanotan II?

Melanotan II is a synthetic cyclic melanocortin agonist developed from alpha-MSH analog chemistry. It is best known for tanning, libido, nausea, appetite, and pigmentation effects. [1][2][3]

Unlike bremelanotide or afamelanotide, Melanotan II is not an FDA-approved drug product. Regulators have warned against injectable tanning products and unapproved supply. [1][2][3]

Its broad melanocortin activity is the core issue: the same pathway that can darken skin or affect sexual response can also affect nausea, blood pressure, appetite, moles, and pigmentation safety. [1][2][3]

What Melanotan II is investigated for

Melanotan II evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Skin tanning and pigmentation

Injectable

52% Emerging

Tanning is human-studied but not an approved or low-risk consumer use. [1][4][6]

Human evidence

A pilot phase 1 study evaluated melanotan II pigmentation, while regulators warn against injectable tanning products. [1][4][6]

Animal / mechanistic evidence

Melanocortin receptor activity explains pigmentation effects, but safety and product-quality concerns are substantial. [1][4][6]

Sexual function enhancement

Injectable

45% Preliminary

Sexual-function discussion should point readers toward the stronger PT-141 evidence boundary. [2][4]

Human evidence

Early human melanotan II literature reported sexual-function effects, but PT-141/bremelanotide is the derivative with approved HSDD evidence. [2][4]

Animal / mechanistic evidence

Central melanocortin arousal biology supports the sexual-function signal. [2][4]

Appetite and food-intake signaling

Injectable

24% Limited

Appetite suppression is preclinical melanocortin signaling, not weight-loss evidence. [22][4]

Human evidence

Human appetite or weight-loss outcomes for melanotan II are not established in the cited literature. [22][4]

Animal / mechanistic evidence

Mouse work links melanotan II with food-intake reductions and energetic responses through melanocortin biology. [22][4]

Evidence snapshot

Overall confidence

Preliminary

45%

Melanotan II has visible melanocortin activity, but the evidence profile is constrained by unapproved injectable safety concerns. Pigmentation and sexual-function signals remain high-caution. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

52%

Human evidence

Emerging

Human tanning effects have been observed, but unapproved injectable tanning use has major safety and regulatory concerns. [1][2][3][4]

34%

Animal / preclinical

Limited

Melanocortin MC1R biology supports pigmentation effects. [1][2][3][4]

49%

Mechanism support

Preliminary

Melanotan II activates multiple melanocortin receptors. MC1R activity supports eumelanin production, while central melanocortin effects help explain libido, appetite, nausea, and flushing. [1][2][3][4]

Forms & administration

Melanotan II is tracked as an injectable unapproved tanning and appetite-related peptide. It is separate from the approved afamelanotide implant used for EPP. [6][7][1]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable Melanotan II protocols usually use 250-500 mcg per dose. [6][7][1]

Frequency

Common injectable calendars use once-daily entries during the loading or active block. [6][7][1]

Timing Considerations

Evening timing is the common anchor; sun-exposure timing belongs in safety behavior rather than dose escalation. [6][7][1]

Cycle Length

Common injectable blocks run 4-8 weeks before comparing pigmentation, appetite, mole changes, nausea, and cardiovascular symptoms. [6][7][1]

What to expect

First 1-2 weeks

Injectable Melanotan II tanning-oriented use may bring early pigment darkening, appetite change, libido change, or tanning-response shifts. [1][2][3][4][6][7]

Weeks 2-6

Injectable tanning blocks may show progressive skin darkening, uneven pigmentation, appetite effects, and libido-pattern changes. [1][2][3][4][6][7]

After stopping

Pigmentation gradually fades after injectable Melanotan II use ends as skin turnover and sun-exposure patterns change. [1][2][3][4][6][7]

Safety profile

Melanotan II safety is high-concern because unapproved injectable tanning use combines melanocortin effects, mole/pigmentation changes, cardiovascular symptoms, and product-quality risk. [6][1][2][3]

Common side effects

Nausea [6][1][2][3]
Flushing [6][1][2][3]
Appetite change [6][1][2][3]
Libido change [6][1][2][3]

Cautions

Moles / melanoma [6][1][2][3]
Cardiovascular symptoms [6][1][2][3]
Unapproved injectable [6][1][2][3]

What we don't know

Long-term melanoma risk, product purity, dose-response, and repeated-cycle cardiovascular safety remain unclear for Melanotan II. [6][1][2][3]

Who Melanotan II is not for

Route-specific avoid and medical-review notes:

History of melanoma or concerning moles
History of melanoma or concerning moles warrants medical review or avoidance for Melanotan II. [6][1][2][3]
Pregnancy or breastfeeding
Pregnancy or breastfeeding warrants medical review or avoidance for Melanotan II. [6][1][2][3]
Uncontrolled cardiovascular disease
Uncontrolled cardiovascular disease warrants medical review or avoidance for Melanotan II. [6][1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Vasoactive sexual-function drugs
PDE5 inhibitors, nitrates, stimulants, or antihypertensives can compound flushing, dizziness, blood-pressure symptoms, or erection effects; this is a theoretical pathway caution. [6][1][2][3]
Appetite / weight-loss drugs
GLP-1 drugs, stimulants, or appetite-suppressant supplements can add nausea and appetite suppression; this is a theoretical pathway caution. [6][1][2][3]
Photosensitizers / tanning products
Photosensitizing drugs or tanning products can increase burn or skin-injury risk if Melanotan II encourages more UV exposure; this is a route-specific caution. [6][1][2][3]

Regulatory status

United States

In the U.S. as of 2026-06-21, Melanotan II is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [13][7][8][11][12]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Melanotan II is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [7][8][11][12]	Flagged FDA safety-risk materials flag Melanotan II for immunogenicity and impurity concerns, plus serious published case-report events. This is a 503A compounding safety-risk bucket, not FDA drug approval. [13][7][8][11][12]

Injectable

FDA drug approval

Not Approved

Melanotan II is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [7][8][11][12]

503A compounding

Flagged

FDA safety-risk materials flag Melanotan II for immunogenicity and impurity concerns, plus serious published case-report events. This is a 503A compounding safety-risk bucket, not FDA drug approval. [13][7][8][11][12]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [14][15][16][17]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Melanotan II injectable route as athlete-cleared without sport-specific review. [9][7][8][11][12]

How it works

Melanotan II activates multiple melanocortin receptors. MC1R activity supports eumelanin production in melanocytes, while central melanocortin effects can influence libido, appetite, nausea, flushing, and autonomic symptoms. [1][2][3][4]

Injectable systemic exposure is the practical concern because this is not just a local cosmetic pigment signal. Broad receptor activity, mole or pigmentation changes, cardiovascular symptoms, priapism reports, and product-quality uncertainty make the mechanism a caution point. This is why route-specific safety and dermatologic monitoring matter more than the tanning shorthand for human use. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about Melanotan II:

A key evidence gap is long-term dermatology outcomes. [1][2][3][4]

A key evidence gap is product-quality surveillance. [1][2][3][4]

A key evidence gap is comparative safety versus approved melanocortin drugs. [1][2][3][4]

Common questions

Is Melanotan II FDA-approved?

No. Melanotan II is not FDA-approved in the U.S., and FDA lists it with significant compounding safety concerns. [7][8][6][1][13][11]

Is Melanotan II a safe tanning shortcut?

No. Regulators warn against unapproved injectable tanning products, and pigmentation, mole changes, cardiovascular symptoms, and product quality are major issues. [7][8][6][1]

Is Melanotan II the same as PT-141?

No. Bremelanotide/PT-141 has a specific FDA-approved indication, route, and label; Melanotan II does not. [7][8][6][1]

Myths & misconceptions

Myth

A darker tan means safer sun exposure.

Reality

Pigmentation does not replace sunscreen, UV avoidance, or mole monitoring. [1][2][3][4]

Myth

Injectable tanning is just cosmetic.

Reality

Injectable melanocortin agonists can affect nausea, blood pressure, appetite, libido, and moles. [1][2][3][4]

History & discovery

Melanotan II emerged from melanocortin analog research that tested tanning, sexual-response, and appetite-related biology. Its later history shifted toward unapproved injectable tanning-market risk. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4][6]

Pilot human studies observed pigmentation and sexual-response signals, along with tolerability issues. Those findings explain public fascination but did not produce an approved tanning medicine. [1][2][3][4][6]

Case reports and regulator warnings moved Melanotan II into a safety story about unapproved injections, pigmentation changes, cardiovascular symptoms, priapism, and product quality. [1][2][3][4][6]

Published research 9 studies

[1]

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.

Life Sci, 1996. human clinical.

[2]

Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.

Int J Impot Res, 2000 Oct. human clinical.

[3]

Melanotan II: a possible cause of renal infarction: review of the literature and case report.

CEN Case Rep, 2020 May. review.

[4]

Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.

Peptides, 2006 Apr. review.

[5]

Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.

Clin Toxicol (Phila), 2012 Dec. review.

[6]

Melanotan and other injectable tanning products

Therapeutic Goods Administration. regulatory.

[7]

Drugs@FDA/openFDA query for Melanotan II

U.S. Food and Drug Administration. database query.

[8]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[9]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.